文献速递胸部肿瘤

克唑替尼在晚期或转移性ROS1重排肺癌患者中的安全性与疗效(EUCROSS):一项欧洲II期临床试验

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
PubMed 文献 · J Thorac Oncol · 2019-04-09

EUCROSS是一项多中心单臂II期试验,评估克唑替尼250毫克每日两次治疗欧洲ROS1重排晚期/转移性肺癌患者。可评估的30例患者中,研究者评估的客观缓解率为70%(95%CI 51-85),中位无进展生存期为20.0个月(95%CI 10.1-未达到)。TP53共突变患者的中位无进展生存期显著短于野生型患者(7.0个月 vs 24.1个月,p=0.022)。

要点

  • 克唑替尼250毫克每日两次在ROS1重排肺癌中研究者评估客观缓解率为70%(95%CI 51-85)。
  • 中位无进展生存期为20.0个月(95%CI 10.1-未达到),CD74-ROS1阳性患者有更高缓解率和更长无进展生存期趋势。
  • TP53共突变患者中位无进展生存期显著短于野生型(7.0个月 vs 24.1个月,p=0.022)。

核心结论

  • 克唑替尼在ROS1重排肺癌患者中高度有效且安全。
  • ROS1-/TP53共突变患者结局显著差于TP53野生型患者。

研究设计与样本

  • 多中心、单臂II期试验(Clinicaltrial.gov标识:NCT02183870)。
  • 入组标准为18岁及以上、经中心确认(荧光原位杂交)的ROS1重排晚期/转移性肺癌患者。
  • 治疗为克唑替尼250毫克每日两次。
  • 主要终点为研究者评估的客观缓解率(实体瘤疗效评价标准1.1版)。
  • 关键次要终点包括无进展生存期、总生存期、独立影像学评估疗效、安全性、健康相关生活质量和肿瘤组织分子特征。

主要发现

  • 34例患者接受治疗,4例被排除在疗效分析之外。
  • 研究者评估的客观缓解率为70%(95%CI 51-85;30例中21例)。
  • 中位无进展生存期为20.0个月(95%CI 10.1-未达到)。
  • DNA测序评估为ROS1野生型序列的2例患者最佳疗效为进展。
  • CD74-ROS1阳性患者有更高客观缓解率和更长中位无进展生存期的趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a prospective phase II trial evaluating crizotinib in European ROS1-positive patients (EUCROSS). PATIENTS AND METHODS: The trial was a multicenter, single-arm phase II trial (Clinicaltrial.gov identifier: NCT02183870). Key eligibility criteria included patients who were 18 years of age or older with advanced/metastatic lung cancer and centrally confirmed ROS1-rearranged lung cancer (fluorescence-in situ hybridization). Treatment included 250 mg crizotinib twice daily. The primary endpoint was investigator-assessed objective response rate (ORR) (Response Evaluation Criteria in Solid Tumors, version 1.1). Key secondary endpoints were progression-free survival (PFS), overall survival, efficacy by independent radiologic review, safety, health-related quality of life, and molecular characterization of tumor tissue. RESULTS: Thirty-four patients received treatment. Four patients were excluded from efficacy analysis. Investigator ORR was 70% (95% confidence interval [CI]: 51-85; 21 of 30 patients) and median PFS was 20.0 months (95% CI: 10.1-not reached). Two patients with ROS1 wild-type sequences assessed by DNA sequencing had progression as best response. CD74-ROS1-positive patients had a trend towards a higher ORR and longer median PFS. TP53-co-mutant patients had a significantly shorter median PFS than wild-type patients (7.0 months, 95% CI: 1.7-20.0 versus 24.1 months, 95% CI: 10.1-not reached; p = 0.022). Treatment-related adverse events were documented in 33 of 34 patients (97%). CONCLUSIONS: Crizotinib is highly effective and safe in patients with ROS1-rearranged lung cancer. ROS1-/TP53-co-aberrant patients had a significantly worse outcome compared to TP53 wild-type patients.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Michels S, Massutí B, Schildhaus HU, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019. PMID: 30978502. doi:10.1016/j.jtho.2019.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。